Viewing Study NCT06643494


Ignite Creation Date: 2025-12-25 @ 1:32 AM
Ignite Modification Date: 2025-12-31 @ 2:38 PM
Study NCT ID: NCT06643494
Status: SUSPENDED
Last Update Posted: 2025-03-11
First Post: 2024-10-10
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical
Sponsor: Optimal Health Research
Organization:

Study Overview

Official Title: Alleviating Androgen Deprivation Therapy (ADT) + External Beam Radiation (EBR) Treatment Side Effects in Prostate Cancer Patients
Status: SUSPENDED
Status Verified Date: 2025-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: PPI currently unable to continue.
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Does nutraceutical N-111 lower the number of side effects occurring during ADT + External Beam Radiation (EBR) prostate cancer treatment?
Detailed Description: Researchers will compare nutraceutical N-111 to a placebo (a look-alike substance that contains no active ingredients) and control group to see if N-111 works to alleviate side effects of prostate cancer treatment.

Participants will:

Take N-111 or a placebo by mouth every day for the duration of the ADT + EBR therapy. Fill out the self-evaluation reporting form weekly during EBR therapy and every three months during ADT therapy to assess their symptoms or lack of symptoms.

The patients will see a physician once a week during the EBR therapy and once every three months for the duration of the ADT therapy.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: